Children in the world’s poorest countries could receive vaccination against rotavirus diarrhoeal disease

Merck commends GAVI Alliance on continued efforts to improve access
Merck commends the GAVI Alliance and donor organisations, governments and partners for their commitment to protecting the lives of children from vaccine preventable diseases and for the continued commitments announced today...

Biogen Idec receives approval in the European Union for AVONEX(R) PEN(TM)
Biogen Idec has announced that the European Commission has granted approval to AVONEX PEN for patients with relapsing multiple sclerosis (MS) and patients who have had a single demyelinating event...

New data in breast and ovarian cancer presented at ASCO support continued development of Iniparib
Sanofi has announced new data for iniparib (BSI-201), an investigational agent, in metastatic triple-negative breast cancer (mTNBC), platinum-sensitive and platinum-resistant recurrent ovarian cancer...

Merck and ARIAD announce presentation of results of Phase III SUCCEED trial
Merck and ARIAD Pharmaceuticals, Inc. have announced the presentation of detailed results from the Phase III SUCCEED clinical trial...

Novartis gains European Commission approval for Lucentis®
The European Commission has granted Novartis a new indication for Lucentis® (ranibizumab) to treat patients with visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO and central RVO)...

ZALTRAP™ (aflibercept) significantly improved survival in previously treated metastatic colorectal cancer patients
Data showing that the investigational agent ZALTRAP™ (aflibercept), also known as VEGF Trap, significantly improved survival in previously treated metastatic colorectal cancer patients will be presented at the ESMO World Congress on Gastrointestinal Cancer on June 25, 2011...

Patients with deadly form of lung cancer lived longer without disease worsening
Eli Lilly and Company has announced that PARAMOUNT, its Phase III study evaluating ALIMTA® (pemetrexed for injection) in the continuation maintenance setting, met its primary endpoint of progression-free survival, or the time a patient is alive without their disease worsening, for patients with a specific type of lung cancer called advanced nonsquamous non-small cell lung cancer (NSCLC)...

Second Phase 3 Study of YERVOY™ (ipilimumab) in Metastatic Melanoma Meets Primary Endpoint of Overall Survival
Bristol-Myers Squibb Company has announced results from a second Phase 3 randomized, double blind study demonstrating that YERVOY™ (ipilimumab) prolonged the lives of patients with metastatic melanoma...

Roche announces vemurafenib improved survival in people with metastatic melanoma who have BRAF V600 mutations
Roche has announced that a Phase III study (BRIM3) showed vemurafenib (RG7204, PLX4032) significantly improved overall survival in people with previously untreated BRAF V600 mutation...

Roche announces data to show Avastin based regimen halved the risk of disease getting worse in women with recurrent ovarian cancer
Roche has announced results from OCEANS, a phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy (gemcitabine and carboplatin) followed by the continued use of Avastin alone in women with previously treated (recurrent) platinum-sensitive ovarian cancer...

Late-breaking ASCO data demonstrate circulating tumor cells as potential biomarker for metastatic prostate cancer clinical trials
Data presented at the 47th American Society of Clinical Oncology (ASCO) annual meeting demonstrate the potential of circulating tumor cells (CTC) as a biomarker for metastatic prostate cancer clinical trials...